BioRestorative Therapies (BRTX) Operating Leases (2019 - 2024)
BioRestorative Therapies' (BRTX) quarterly Operating Leases came in at $42414.0 in Q3 2024, down 78.66% YoY from $198724.0 in Q4 2023, and down 49.25% on a QoQ basis from $83580.0 in Q2 2024.
BioRestorative Therapies (BRTX) Operating Leases (2019 - 2024) Analysis & Trends
BioRestorative Therapies (BRTX) has 6 years of Operating Leases data on file, last reported at $42414.0 in Q3 2024.
- Quarterly Operating Leases fell 78.66% year-over-year to $42414.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $42414.0 (down 78.66% YoY) and the FY2023 annual result came in at $162317.0, changed 0.0% from the prior year.
- Operating Leases eased to $42414.0 in Q3 2024, from $83580.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $497714.0 in Q1 2020 to a low of $42414.0 in Q3 2024.
- A 5-year average of $255364.7 and a median of $234060.0 in 2022 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2023 — Operating Leases changed 0.0% — and 2024, when it sank 78.66%.
- Tracing BRTX's Operating Leases over 5 years: stood at $363519.0 in 2020, then dropped by 17.02% to $301645.0 in 2021, then tumbled by 46.19% to $162317.0 in 2022, then changed by 0.0% to $162317.0 in 2023, then sank by 73.87% to $42414.0 in 2024.
- The last three Operating Leases figures came in at $42414.0 (Q3 2024), $83580.0 (Q2 2024), and $123536.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 42,414.00 |
| Jun 30, 2024 | 83,580.00 |
| Mar 31, 2024 | 123,536.00 |
| Dec 31, 2023 | 162,317.00 |
| Sep 30, 2023 | 198,724.00 |
| Jun 30, 2023 | 83,580.00 |
| Mar 31, 2023 | 123,536.00 |
| Dec 31, 2022 | 162,317.00 |
| Sep 30, 2022 | 198,724.00 |
| Jun 30, 2022 | 234,060.00 |
| Mar 31, 2022 | 268,357.00 |
| Dec 31, 2021 | 301,645.00 |
| Sep 30, 2021 | 332,755.00 |
| Jun 30, 2021 | 362,949.00 |
| Mar 31, 2021 | 392,256.00 |
| Dec 31, 2020 | 363,519.00 |
| Sep 30, 2020 | 447,142.00 |
| Jun 30, 2020 | 472,805.00 |
| Mar 31, 2020 | 497,714.00 |
| Dec 31, 2019 | 521,890.00 |